


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Please amend claim 18 and add new claims 30-34 as follows:

1-17. (Canceled)

18. (Currently Amended) A method of treating leukemia, ~~colon cancer, breast cancer or prostate cancer~~ comprising administering to a patient with said ~~disease~~ leukemia an effective amount of 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ having the formula:



19. (Original) The method of claim 18 wherein 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ is administered orally.


20. (Original) The method of claim 18 wherein 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ is administered parenterally.

21. (Original) The method of claim 18 wherein 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ is administered transdermally.

22. (Original) The method of claim 12 wherein 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ is administered in a dosage of from about 0.01 μ g/day to about 10 μ g/day.

23-29. (Canceled)

30. (New) A method of treating colon cancer, breast cancer or prostate cancer comprising administering to a patient with said disease an effective amount of 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ having the formula:



31. (New) The method of claim 30 wherein 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ is administered orally.

32. (New) The method of claim 30 wherein 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ is administered parenterally.

33. (New) The method of claim 30 wherein 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ is administered transdermally.

34. (New) The method of claim 30 wherein 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ is administered in a dosage of from about 0.01 μ g/day to about 10 μ g/day.